Joerg Windisch, the former chief science officer at Sandoz Biopharmaceuticals (Novartis), has joined Affimed NV in Heidelberg, Germany as chief operating officer to help advance that company’s pipeline of bispecific antibody therapeutics. At Sandoz, Dr Windisch played a leading role in the development of omnitrope, the first biosimilar medicine to be approved for marketing. Dr Windisch was educated in Europe and the US, receiving a PhD in biochemistry and molecular biology from the University of Innsbruck in Austria.
Affimed announced the appointment on 21 January 2016.
Copyright 2016 Evernow Publishing Ltd